Hoechst Marion Roussel Funds Outcomes Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.

Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.

Articles in this issue
Studies of Counselings' Impact on Survival Challenged
Telomerase Activity Potential Marker for Bladder Cancer
HIV Has Become a Specialty Disease, But One Open to the Well-Informed Generalist
Writing Genetic Testing Guidelines Complex Endeavor
AACR Meeting Sees Growth Spurt in Telomerase Research
DDT Appears to Activate Human Estrogen Receptors
Studies Highlight Role of bcl-2 Gene in Programmed Cell Death
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmed
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancers
Traveling Exhibit of Cancer Educational Resources
History of Substance Abuse Not a Barrier to Opioid Use
Support Program for Melanoma Patients Receiving Interferon
Taxol/Adriamycin as First-Line Metastatic Breast Cancer Therapy
New Cancer Websites, New Features Join the Information Highway
Dying in Hospital May Be Preferable to Dying at Home

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Related Content
Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.